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Summary
Objective: The purpose of this study was to determine the effects of long-term estrogen replacement therapy (ERT) on insulin-like growth
factor binding protein (IGFBP)-2, IGFBP-3, collagen and proteoglycan levels in the articular cartilage of the knee joint in a well-characterized
monkey model of naturally occurring osteoarthritis (OA). A secondary aim was to evaluate the effect of soy phytoestrogen treatment on these
articular cartilage components.
Design: Monkeys were ovariectomized and given ERT, soy phytoestrogen treatment or no treatment (control) for 3 years. Ten animals were
randomly selected from each of the three groups and the cartilage was dissected from the proximal tibia and distal femur of the knee. Levels
of IGFBP-2, IGFBP-3, and total protein were measured in cartilage desorptions, and proteoglycan levels and collagen levels were measured
in the cartilage tissue. Sections from the tibial plateau of the opposite knee were immunostained using antibodies directed against IGFBPs
and evaluated subjectively.
Results: IGFBP-3 levels were significantly higher, and total protein levels were significantly lower in the cartilage desorption samples from
the estrogen-treated animals compared to the control animals. There were no significant differences in IGFBP-2, collagen or proteoglycan
levels between the estrogen-treated and control groups. Soy phytoestrogen treatment had no significant effect on the levels of any of the
cartilage components that were measured. The staining patterns observed by immunohistochemistry suggested local production of IGFBP-2
and IGFBP-3 by articular cartilage chondrocytes.
Conclusions: Long-term estrogen treatment results in increased IGFBP-3 levels in articular cartilage without a significant change in IGFBP-2,
collagen or proteoglycan content, and IGFBP-3 appears to be synthesized by articular cartilage chondrocytes. Long-term soy phytoestrogen
treatment did not have a statistically significant effect on the levels of IGFBP-2, IGFBP-3, collagen or proteoglycan.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Osteoarthritis, Animal model, Insulin-like growth factor binding protein (IGFBP), Cartilage.
Abbreviations: ANOVA, analysis of variance, ELISA, enzyme-linked immunosorbent assay, ERT, estrogen replacement therapy, IGF,
insulin-like growth factor, IGFBP, insulin-like growth factor binding protein, OA, osteoarthritis, RIA, radioimmunoassay.
Introduction
The risk of developing osteoarthritis (OA) increases for
women after menopause, and it is thought that estrogen
deficiency accompanying menopause may be a risk factor
for developing the disease. Although there are some con-
flicting results among the epidemiological studies of women
and OA, most show that estrogen replacement therapy
(ERT) is associated with reduced severity and prevalence
of OA in postmenopausal women1. We recently published
evidence in an animal model that further supports this
association, showing that long-term ERT in cynomolgus
macaques reduced the severity of histological cartilage
lesions of naturally occurring OA2.
Cynomolgus macaques develop OA naturally as they
age, and the histological lesions that develop in the tibial
plateaus and femoral condyles of these animals are
very similar to those occurring in humans3–5. In addition,
ovariectomized cynomolgus macaques are a well-
characterized animal model of postmenopausal ERT and
have been used to study its effects on several important
diseases of aging women, including OA2, atherosclerosis6,
and osteoporosis7.
Although the mechanism behind the protective effect of
estrogen against lesions of OA is unknown, it has been
proposed that the direct interaction of estrogen with
chondrocyte estrogen receptors could lead to anabolic
effects on the cartilage tissue. Estrogen receptors have
been demonstrated in chondrocytes from many species,
including humans8–11, and these receptors have been
shown to be functional in chondrocytes from the knee
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articular cartilage of cynomolgus macaques9. Recent
studies by our group suggest that in vivo estrogen treat-
ment may upregulate the insulin-like growth factor (IGF)
system in the articular cartilage of ovariectomized cynomol-
gus monkeys9,12. In a previous study, synovial fluid levels
of IGF-1 and IGF-2, and IGF binding protein (IGFBP)-1 and
IGFBP-3 were significantly increased in ovariectomized
monkeys that were treated with ERT in vivo, when com-
pared to their untreated ovariectomized counterparts12.
The effect of an increased level of IGFBP-1 or -3 in the
synovial fluid is unknown. IGFBP-3 is present in articular
cartilage, and has increased expression and synthesis in
end-stage OA cartilage13,14. In normal cartilage it is com-
plexed with IGF and fibronectin in the pericellular region15,
and in late stage OA, it has been shown to be complexed
with IGF and the acid-labile subunit (ALS) as in serum16.
Little is known regarding the function of IGFBP-3 in carti-
lage, and it is not clear if it acts to enhance or reduce the
cell’s response to IGF-1. In an in vitro study using human
cartilage explants from normal and OA joints, co-incubation
of IGF-1 and recombinant IGFBP-3 did not affect proteogly-
can synthesis in either normal or OA tissue, while IGFBP-3
pre-incubation in a group of OA explants enhanced the
IGF-1 stimulated proteoglycan synthesis, with a similar
enhancement noted in non-OA cartilage17. In a previous
study of cultured chondrocytes isolated from cartilage
removed from the knees of ovariectomized estrogen-
treated cynomolgus monkeys, we noted increased levels of
IGFBP-2 in the culture medium when compared to cells
from animals that were not treated with hormones9. In
addition, this increase in IGFBP-2 was associated with an
increase in the production of proteoglycans by the chondro-
cytes. It was suggested that the increased levels of IGF in
the synovial fluid may be transferred to the upregulated
IGFBP-2 in the articular cartilage, where it would be stored
and released, as needed, to cause chondrocytes to pro-
duce more cartilage matrix components9. In order to further
explore this hypothesis in the present study, IGFBP-2 as
well as IGFBP-3 levels were measured directly in the
tissue.
The primary objective of the present study was to evalu-
ate the effects of ERT on the knee articular cartilage of the
monkeys; however, cartilage tissue from an additional
treatment group that was ovariectomized and treated with
soy phytoestrogens was evaluated as well. Dietary soy
phytoestrogens are thought to be a potential alternative to
traditional ERT, and although they are not as well-
characterized as estrogen, studies suggest that they may
provide similar health benefits, such as a decreased risk of
coronary artery disease6 and osteoporosis18–20. Soy phy-
toestrogens are derived from plants and possess estrogen-
like activity. They are known to combine with estrogen
receptors at a much lower affinity than estrogen, but have
been shown to produce the same maximal receptor
response at high doses in vitro21. Our previous histological
study evaluated the medial tibial plateaus of the opposite
knee of the same group of animals that are included in the
present study. The results showed that the tibial plateaus of
the soy phytoestrogen-treated animals contained OA
lesions that were intermediate in severity between the
untreated animals and the estrogen-treated animals;
however, the differences were not statistically significant2.
The purpose of the present study was to determine if
there were differences in the biochemical composition of
articular cartilage in monkeys receiving ERT or soy phy-
toestrogens compared with untreated control monkeys. We
measured levels of IGFBP-2 and IGFBP-3 in the articular
cartilage tissue of these animals, and also studied the
distribution of IGFBPs in the tibial plateaus of the opposite
knee using immunohistochemistry. Also, to test the hypoth-
esis that ERT increases chondrocyte production of
cartilage matrix components, we measured levels of
hydroxyproline and proteoglycan in the tissue.
Methods
ANIMALS AND STUDY DESIGN
The animals used in this study were subjects in an
experiment that was designed to study the effects of
estrogen deficiency, exogenous estrogen treatment and
soy phytoestrogen treatment on atherosclerosis of the
coronary arteries and this has been previously described in
detail2,6. Briefly, the study included 180 feral adult female
cynomolgus monkeys that were given water ad libitum and
were fed a moderately atherogenic diet (40% of calories
from fat) for 26 months6. At the end of this 26-month period
the monkeys were bilaterally ovariectomized to simulate
menopause, and were randomly divided into three age-
and weight-matched treatment groups using a stratified
randomization scheme6: (1) control group (n60); (2)
estrogen-treated group (Premarin™ [conjugated equine
estrogens], Wyeth-Ayerst Laboratories) (n60); and (3)
soy phytoestrogen-treated group (n60). The treatments
were administered in the diet, with estrogen given at an
equivalent dose of 0.625 mg/day for women, and soy
phytoestrogen given at a dose approximately equivalent to
129 mg/day for women (generously provided by Protein
Technologies International, St. Louis, MO [SUPRO 670-
HG]). The treatments were given for 36 months, during
which all three groups were fed a moderately atherogenic
diet6.
The average age of the monkeys selected for this study,
as estimated by dentition22, was 11.8 years (range=10.6–
13.7 years) at necropsy, which is approximately equivalent
to 35 human years. The average age at ovariectomy was
8.8 years (range=7.6–10.7 years).
NECROPSY AND TISSUE PREPARATION/HANDLING
At necropsy both knee joints were collected. The right
knee was used for histological evaluation2 and the left knee
was frozen intact at −70°C. Ten of the frozen knees from
each treatment group were selected randomly and thawed.
Each knee was opened with a scalpel blade and the
meniscus and patella were removed. Articular cartilage was
carefully dissected from the tibial plateaus and femoral
condyles so that the subchondral bone was not disturbed.
Articular cartilage was then pooled from all sites, and a
wet weight was obtained. The amount of cartilage
collected from each knee ranged from 281 to 517 mg
(average=394 mg) of wet weight cartilage.
DESORPTION AND MEASUREMENT OF IGFBP-2 AND IGFBP-3
IGFBP-2 and IGFBP-3 were desorbed from the cartilage
by incubating it in a buffer consisting of 20 mM Tris base,
137 mM NaCl and 10 mM ethylenediamine tetra acetate
(modified technique from Schneiderman et al.16). The
buffer was brought to pH 7.4 with HCl, and autoclaved for
30 min. After the buffer was cooled to room temperature,
1 mM N-ethylmaleimide, 1/100 protease inhibitor cocktail
(Sigma, St. Louis, MO) and 1/100 antibiotic/antimycotic
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(GibcoBRL, Rockville, MD) solution were added. Cartilage
samples were incubated for 3 days in 3 ml of buffer per
gram of wet weight cartilage. This procedure was done
three times and the three desorptions were maintained as
separate samples.
IGFBP-2 was measured by running the desorption
samples on the IGFBP-2 radioimmunoassay (RIA) from
Diagnostic Systems Laboratories (Webster, TX)
(sensitivity=0.5 ng IGFBP-2 per ml of serum). The IGFBP-3
enzyme-linked immunosorbent assay (ELISA) kit from
Diagnostic Systems Laboratories (Webster, TX) was used
to measure levels of IGFBP-3 in the desorption samples
(sensitivity=0.04 ng IGFBP-3 per ml of serum). Both assays
measure total IGFBP-2 or -3 (both free and complexed to
IGF-1 or IGF-2), and the IGFBP-3 ELISA may also
measure some IGFBP-3 fragments. Assays were run on all
three neat cartilage desorption samples for each cartilage
specimen, and the concentration of IGFBP-2 and IGFBP-3
in the cartilage desorption samples was highest in desorp-
tion 1, lower in desorption 2 and lowest in desorption 3, as
expected.
We verified that the desorption technique adequately
extracted IGFBP-2 in a preliminary experiment by using an
8 M urea extraction technique (previously described23) on
the cartilage after the desorption process was complete.
The experiment included the cartilage from four monkey
knees and samples were run in duplicate. For three of the
four animals the results of the 8 M urea extraction showed
no or very low (maximum 0.006 ng/mg wet weight cartilage)
detectable levels of IGFBP-2 after the desorption pro-
cedure. The results of the duplicates for the fourth sample
did not match, so it was not used to evaluate the desorption
technique.
DYE-BINDING ASSAY FOR PROTEOGLYCANS
After each desorption experiment the cartilage residue
was digested in protease K (1 mg/ml), and the proteogly-
can content was measured using the glycosaminoglycan
dye-binding assay24. Briefly, samples were diluted in a
buffer containing 0.24 M guanidine hydrochloride and
0.05 M sodium acetate at pH 6.8. Samples were run in
triplicate on a 96-well plate, and rat chondrosarcoma
proteoglycan D1.524 was used as a standard. 1,9-
Dimethylmethylene blue with sodium formate was added to
the samples and standards, and the optical density of each
well was read on an automatic plate reader at a dual
wavelength of 550/650 nm.
HYDROXYPROLINE ASSAY
The hydroxyproline content was measured in the di-
gested cartilage residue samples using the hydroxyproline
assay24. Briefly, 2 mg of digested cartilage was hydrolyzed
in 6 N HCl for 20–24 h at 110°C. The dried samples were
resuspended in water. All samples and hydroxyproline
standards (0–40 µg/ml) were run in duplicate. Five hundred
microliters of sample or standard was incubated with
0.05 M CuSO4 and 500 µl 2.5 N NaOH for 5 min at
40°C, and then 500 µl of 6% H2O2 was added and
for an additional 10 min at 40°C. After cooling to room
temperature, 2 ml of 3 N H2SO4 and 1 ml 5%
p-dimethylaminobenzaldehyde were added, incubated for
16 min at 70°C and cooled to room temperature. Each
sample (200 µl) was read at a wavelength of 550 nm in a
96-well plate. Collagen levels were calculated from
hydroxyproline levels assuming that 11% of collagen is
composed of hydroxyproline25.
PROTEIN ASSAY AND SODIUM DODECYL
SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS
The total protein was measured in each of the three
desorption samples for each cartilage specimen using the
Pierce BCA Protein Assay (Rockford, IL) microwell plate
protocol. Bovine serum albumin was used as the standard
and was diluted in desorption buffer.
To evaluate protein content, desorption samples from
four animals from the ERT group and four animals from the
control group were chosen based on the amount of sample
remaining after the IGFBP and total protein assays were
completed. Desorptions 1, 2 and 3 were combined for
each sample and were concentrated and desalted on
Ultrafree-MC filter columns with a molecular weight cutoff of
5 kDa (Millipore, Bedford, MA). Protein (30 µg) was lyophi-
lized and resuspended in 30 µl of sample buffer, boiled for
5 min and loaded onto a 4–20% precast Tris–HCl poly-
acrylamide mini gel (BioRad, Hercules, CA) and electro-
phoresed. The protein bands were visualized by staining
overnight in 0.075% Coomassie blue R-250 in 50% metha-
nol and 10% acetic acid, and destained with 50% methanol
and 10% acetic acid in water.
IMMUNOHISTOCHEMISTRY
A mid-coronal section of the right tibial plateau was
decalcified, embedded in paraffin, and sectioned at 6 µm.
Two separate protocols were used to immunostain for
IGFBPs.
Tissues were immunostained for IGFBP-2 and -3 using
the Dako Autostainer Universal Staining System (Dako
Corporation, Carpinteria, CA) and the Dako LSAB2
System kit (K0673) according to the manufacturer’s instruc-
tions. Briefly, the slides were deparaffinized in xylene, and
treated with a series of 30 s alcohol washes (100, 95 and
70% ethanol), followed by hydration for 1 min in distilled
water and incubated in Tris buffer (50 mM Tris–HCl,
150 mM NaCl, pH 7.6 with 0.05% Tween 20) until ready to
be stained. The slides were treated with 3% hydrogen
peroxide, and incubated in protein block (Dako X0909) to
prevent nonspecific binding. The primary antibodies used
in this portion of the experiment were a protein A purified
mouse anti-human IGFBP-3 (DSL R00538, Diagnostic Sys-
tems Laboratories, Webster, TX), and a protein A purified
mouse anti-human IGFBP-2 (DSL R00445). A control for
supersensitive mouse antibodies (BioGenex, San Ramon,
CA) was used for the negative controls. Slides were incu-
bated for 1 h in a 1:500 dilution of primary antibody in Dako
antibody diluent (Dako S0809). This was followed by a
30-min incubation with the biotinylated link anti-mouse,
anti-rabbit conjugate that was included in the kit, followed
by a 15-min incubation with streptavidin–horseradish per-
oxidase. The slides were then stained with Vector Nova
Red (substrate kit 4800, Vector Laboratories, Burlingame,
CA), and counterstained with Dako Mayer’s hematoxylin
(S3309).
The slides that were immunostained for IGFBP-1 were
deparaffinized in xylene, and treated with a series of 30 s
alcohol washes (100, 95 and 70% ethanol), followed by
hydration for 1 min in distilled water and incubated in Tris
buffer (50 mM Tris–HCl, 150 mM NaCl, pH 7.6 with 0.05%
Tween 20, 5 g/l caseine and two drops of Triton X-100) until
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ready to be stained. The primary antibody used was a
rabbit anti-human IGFBP-1 polyclonal antibody (Upstate
Biotechnology Incorporated, Lake Placid, NY) and a control
for supersensitive rabbit antibodies (BioGenex, San
Ramon, CA) was used for the negative controls. Slides
were incubated for 75 min in a 1:30 dilution of primary
antibody in Dako antibody diluent (Dako S0809), followed
by a 30 min incubation with a biotinylated anti-rabbit conju-
gate (BioGenex, San Ramon, CA). This was followed by a
15-min incubation with streptavidin-alkaline phosphatase
enzyme conjugate (BioGenex, San Ramon, CA). The
slides were then stained using Vector Red (substrate
kit no. 1, Vector Laboratories, Burlingame, CA) and
counterstained with Dako Mayer’s hematoxylin (S3309).
Sections were examined histologically and immunostain-
ing patterns were recorded.
STATISTICAL ANALYSIS
The results of desorptions 1, 2 and 3 for each sample
were added before running the statistical analyses on the
IGFBP-2, IGFBP-3 and total protein assay results.
The results for the ERT group were compared to those
for the control group using a two-sample t-test. In addition,
the soy phytoestrogen group was compared to the control
group using a two-sample t-test, and all three groups were
evaluated using ANOVA and post hoc tests (Tukey
method). In addition, OA severity scores (obtained from our
previous histological study2) for the 30 animals included in
the present study were compared to IGFBP-2, IGFBP-3
and total protein results using regression analysis.
Results
OA LESIONS IN CARTILAGE TISSUE
There were no gross lesions of OA visible in the articular
cartilage upon dissection. In a previous study we found that
there were early histological lesions of OA present in the
medial tibial plateau of the opposite knee of these animals
(i.e., in the previous study2 articular structure scores
were graded from 1 (normal cartilage) to 20 (severe full-
thickness fibrillation), the average score was 5.15
(SD=2.53) (n166) and for the animals included in the
present study the average score was 4.53 (SD=2.21)
(n30)).
CARTILAGE DESORPTION LEVELS OF IGFBP-3, IGFBP-2 AND TOTAL
PROTEIN
All IGFBP-3 was detected in desorption 1 for all of the
samples except for two, which had minimal amounts
detected in desorption 2. There was no IGFBP-3 detected
in desorption 3 for any of the samples. There was a
significantly higher level of IGFBP-3 in the cartilage
desorption samples from the estrogen-treated group
(mean=12.3 pg/mg cartilage) compared to the control
group (mean=3.0 pg/mg cartilage) (t-test, P-value=0.023).
There was no significant difference between the control and
soy phytoestrogen-treated groups (soy phytoestrogen
mean=5.1 pg/mg cartilage) [Fig. 1(a)]. The results were the
same when all three groups were evaluated using ANOVA
and post hoc testing (data not shown).
Fig. 1. Desorption levels of IGFBP-3 (a), IGFBP-2 (b), and total protein (c) per mg of monkey cartilage from animals in the three treatment
groups. Bars represent the mean and standard error, and ** indicates significantly different from control (P<0.05). Results represent the total
of all three desorptions. Soy, soy phytoestrogen.
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IGFBP-2 was detected in all three desorptions for all of
the samples (average for all 30 samples was 97, 75 and
60 pg/mg cartilage for desorptions 1, 2 and 3, respectively).
The differences in IGFBP-2 levels among the three groups
were not statistically significant [Fig. 1(b)]. The levels of
IGFBP-2 were 83.3, 46.9, and 18.7 times higher than levels
of IGFBP-3 in the cartilage desorption samples from the
control, soy phytoestrogen- and estrogen-treated groups,
respectively (IGFBP-2 mean for control=250 pg/mg carti-
lage; soy phytoestrogen=239 pg/mg cartilage; estrogen=
230 pg/mg cartilage). The results of the comparisons
among the three treatment groups for IGFBP-2 and
IGFBP-3 did not change if only the first desorption was
considered, instead of the pool of all three, when perform-
ing statistical analyses.
There was a significantly higher level of total protein in
the cartilage desorption samples from the control group
(mean=4.1 µg/mg cartilage) than in the estrogen-treated
group (mean=3.1 µg/mg cartilage) (t-test, P-value=0.039)
[Fig. 1(c)]. However, there were no visible differences in the
protein banding patterns when the desorption samples
from these two treatment groups were evaluated on a
polyacrylamide gel (data not shown). There was no statisti-
cally significant difference in the level of total protein in the
desorptions from the soy phytoestrogen-treated group
compared to the control group (soy phytoestrogen
mean=3.8 µg/mg cartilage) [Fig. 1(c)], or when all three
treatment groups were compared using analysis of
variance (ANOVA) (data not shown).
In the soy phytoestrogen group, the average levels of
IGFBP-2, IGFBP-3 and total protein were intermediate
between those of the estrogen-treated group and the
control group (Fig. 1).
IMMUNOHISTOCHEMISTRY
The immunohistochemistry sections revealed pericellular
and cellular staining for IGFBP-2, and cellular staining for
IGFBP-3 [Fig. 2(a and b)]. There were no clear differences
in the amount or distribution of staining present among the
Fig. 2. Articular cartilage sections from monkey tibial plateaus, stained for IGFBPs using immunohistochemistry. Positive immunostaining for
IGFBP-2 and IGFBP-3 is reddish-brown (a, b), positive immunostaining for IGFBP-1 is pink (c), and counterstained cells are blue. IGFBP-2
staining showed specific pericellular (closed arrow) and cellular (open arrows) staining throughout the articular cartilage (a). Staining for
IGFBP-3 revealed cellular staining throughout the cartilage, including the deep zones (arrows) (b). Staining for IGFBP-1 revealed superficial
cartilage matrix staining (arrows) (c). Negative control (d). Tissues are from estrogen-treated (a, b), control group (c) and soy
phytoestrogen-treated (d) animals.
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three treatment groups for either binding protein. The
IGFBP-1 immunohistochemistry revealed only superficial
matrix staining [Fig. 2(c)].
OA SCORES VS IGFBP-2, IGFBP-3 AND TOTAL PROTEIN LEVELS
There were no significant correlations between OA
scores2 and IGFBP-2, IGFBP-3 or total protein levels (data
not shown).
CARTILAGE LEVELS OF COLLAGEN AND PROTEOGLYCAN
The levels of collagen were highest in the digested
cartilage residue samples from the estrogen-treated group;
however, there were no significant differences among the
three treatment groups (Table I). In addition, the proteogly-
can levels in the digested cartilage were not significantly
different among the three groups (Table I).
Discussion
This is the first study to document that long-term ERT
results in increased levels of IGFBP-3 in the knee articular
cartilage. The results of this study support the hypothesis
that articular cartilage chondrocytes may synthesize
IGFBP-3 in response to ERT. The levels of IGFBP-3 were
significantly higher in the cartilage extracts from the ERT
group compared to the control group [Fig. 1(a)], and the
immunostained sections of the tibial plateaus revealed
patterns consistent with chondrocyte production of
IGFBP-3 [Fig. 2(b)].
Presently the function of IGFBPs in cartilage is not clear.
Investigators have shown that IGFBPs may regulate the
transport of IGFs in bovine articular cartilage, suggesting
that this may contribute to the control of paracrine activities
by IGFs in this tissue26. In addition, it was shown that
expression of several IGF system components, including
IGF-1, IGFBP-3 and IGFBP-3 proteases, was increased in
human end-stage OA cartilage when compared to normal
cartilage13. It is not clear, however, whether these
increases related to the development of OA or to the repair
process in the cartilage. In the present study, we found no
correlation between histological OA severity scores from
the opposite knee of these same animals (from our pre-
vious study2) and levels of IGFBP-2 or -3; however, these
cartilage samples were from monkeys with relatively mild
OA lesions.
IGFBP-3 is an important mediator of IGF-1 function. It is
known to bind to free IGF-1 and can either inhibit or
promote IGF activity depending on the experimental con-
ditions27,28. In addition, IGFBP-3 appears to have biologi-
cal actions on cells that occur independently of IGF-1 and
IGF-1 receptors. By binding directly to cell surface recep-
tors (e.g., the type V TGF-beta receptor in cultured mink
lung epithelial cells29), IGFBP-3 can stimulate cells inde-
pendently of IGF, and it has also been shown to be
transported to the nucleus in several cell types30,31. This
evidence suggests that IGFBP-3 has other biological func-
tions aside from regulating IGF-1 activity, and it is possible
that IGFBP-3 may have IGF-1 independent functions in
cartilage as well. It has been hypothesized that the in-
crease in IGFBP-3 in end-stage disease contributes to the
disease process by increasing the binding of IGFBP-3 to
IGF-1, resulting in inhibition of IGF-1 and preventing it from
stimulating chondrocytes to produce cartilage matrix com-
ponents13,32. Unlike the studies of human end-stage OA
cartilage, the increase in IGFBP-3 in the present study was
observed in cartilage from animals with early OA. The
physiological role of IGFBP-3 may be different in early OA
compared to advanced OA cartilage. Further study is
needed to investigate this.
It has been shown that estrogen regulates the expres-
sion of IGF-1 through the estrogen–estrogen receptor com-
plex interacting with the activator protein 1 enhancer in the
promoter of the IGF-1 gene in vitro33. In addition, articular
cartilage chondrocytes have been shown to have functional
estrogen receptors9, presenting the possibility that estro-
gen may directly stimulate articular cartilage chondrocytes
to produce IGF system components. In the animals from
the present study, there were less severe OA lesions
present in the articular cartilage of the ERT animals when
compared to the control animals2. It is possible that the
estrogen may be stimulating the synthesis of IGF system
components, including IGFBP-3 in the articular cartilage
chondrocytes, and that the IGFBP-3 may be playing a
protective role in the cartilage by regulating IGF-1 activity,
or by interacting directly with cell surface receptors to
cause anabolic effects in the cartilage tissue.
A study of synovial fluid taken from normal and arthritic
patients34 showed that the levels of IGF-1 and IGFBP-3
were correlated. In the present study, it would have been
useful to know the levels of IGF-1 in the cartilage of these
animals. In preliminary studies, we attempted to measure
IGF-1 in the articular cartilage of monkey knees using a
variety of extraction techniques and a commercially avail-
able ELISA kit. These experiments were unsuccessful,
perhaps due to the small size of the cartilage samples;
therefore the samples were used to investigate IGFBP
levels.
In a previous study, we found that IGFBP-2 levels were
increased in the synovial fluid of monkeys on ERT when
compared to those that were not, but this increase was not
statistically significant12. In addition, when chondrocytes
were cultured from knee articular cartilage from ovariect-
omized monkeys that had been treated with estrogen
in vivo, they released significantly more IGFBP-2 into
the culture medium than control animals9. In contrast, the
present study revealed no significant differences in the
levels of IGFBP-2 in the cartilage desorption samples
among the three treatment groups. Further study is needed
to clarify the role of IGFBP-2 in articular cartilage and its
possible role in OA.
There are some limitations to the IGF/IGFBP component
of this study. No established techniques are available to
measure levels of these compounds in cartilage, and the
ELISA and RIA kits that were used were developed to
measure these proteins in human serum; however, monkey
serum controls confirmed that the antibodies used in the
kits recognize monkey IGF-1, IGFBP-2 and IGFBP-3. In
addition, it is possible that the IGFBPs detected in the
cartilage desorption samples were not produced by the
chondrocytes, and may have diffused into the cartilage
tissue from the synovial fluid. However, this possibility
seems unlikely in light of the staining patterns observed in
the immunohistochemistry studies (Fig. 2). Cellular staining
patterns were observed for both IGFBP-2 and -3 in
both superficial and deep articular cartilage [Fig. 2(a and
b)], suggesting that the chondrocytes are producing
and releasing the binding proteins, rather than the
proteins diffusing from the synovial fluid. In contrast, the
IGFBP-1 immunohistochemistry revealed staining only in
the superficial cartilage matrix [Fig. 2(c)], which may be
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consistent with diffusion from the synovial fluid. In addition,
the IGFBP-3 ELISA that was used in this study may detect
IGFBP-3 fragments as well as intact IGFBP-3. If fragments
were detected as part of the total IGFBP-3 it would suggest
the presence of IGFBP-3 protease activity, and the subse-
quent increased release of IGF to the cells. Given the
present results, there is no way to be certain if IGFBP-3
fragments were measured as part of the total IGFBP-3, or if
ERT increased the levels of intact IGFBP-3 or IGFBP-3
fragments. Finally, we do not know the possible effects of
the atherogenic diet on OA progression; however, previous
studies of this animal model have shown that there is no
difference in OA severity between monkeys treated with the
atherogenic diet and those that were not (unpublished
observations).
Interestingly, the average concentration of IGFBP-2 in
the cartilage desorption samples was considerably higher
than the concentration of IGFBP-3 in all three treatment
groups [Fig. 1(a and b)]. Although the two binding proteins
were measured using different assays (IGFBP-2, RIA;
IGFBP-3, ELISA) the large difference in concentrations
suggests that the cartilage levels of IGFBP-2 are much
higher than the levels of IGFBP-3. These results are
consistent with immunoblot studies on bovine articular
cartilage that showed that IGFBP-2 and IGFBP-6 were the
two most prevalent IGFBPs present in the cartilage23. In
addition, a more recent study done by the same investiga-
tor showed that IGFBP-2 was the most prevalent IGFBP in
human cartilage and that IGFBP-6 was absent35. The
combined results of these studies suggest that IGFBP-2 is
the dominant IGFBP in cartilage, and further study is
warranted to determine its biological significance.
In addition to measuring IGFBP levels in the cartilage
desorption samples, we also measured the protein concen-
tration and found that it was significantly higher in the
samples from the control animals when compared to the
estrogen-treated animals [Fig. 1(c)]. The explanation for
this difference is unclear. We ran selected desorption
samples from the two treatment groups on a polyacryla-
mide gel to determine if we could observe any major
differences between the two groups in the proteins that
were desorbed. On examining the banding patterns on a
polyacrylamide protein gel (not shown), there were no
obvious differences between the desorption samples from
the control group and the estrogen-treated group. However,
the OA lesions were significantly more advanced in the
control group compared to the ERT group2 and, as a
consequence, perhaps the matrix was less well-organized,
allowing more protein to escape into the desorption buffer.
Finally, in a previous study, we showed that chondrocytes
taken from the knees of ovariectomized monkeys that were
treated with ERT in vivo had an increased production of
proteoglycan in culture, compared to those of untreated
animals9. Those results conflict with the results from the
present study in which there were no significant differences
observed in the levels of proteoglycan and collagen in the
cartilage among the three treatment groups (Table I). There
are also conflicting results in the literature regarding the
effect of estrogen on cartilage proteoglycan synthesis. One
study showed that proteoglycan synthesis was decreased
with estrogen treatment in an induced OA rabbit model36;
however, catabolism was decreased so the total proteogly-
can content of the tissue was not reduced. Another study
showed that adding supraphysiologic concentrations of
estrogen to bovine articular cartilage explants and chondro-
cyte cultures decreased the synthesis of proteoglycans,
while physiologic concentrations had no effect37. It is un-
known whether ERT stimulates articular cartilage chondro-
cytes to synthesize cartilage matrix components. The
results of this study suggest that in the early disease
process it may not; however, the conflicting results in the
literature indicate that there is a need for further study in
this area.
In summary, we have shown that IGFBP-3 levels are
increased in the cartilage of estrogen-treated ovariect-
omized cynomolgus monkeys when compared to untreated
ovariectomized controls, and this protein appears to be
synthesized by articular cartilage chondrocytes. This pro-
vides further evidence to indicate that in vivo ERT can
induce an upregulation of some of the IGF system compo-
nents in articular cartilage, but further studies are needed
to determine if these changes are responsible for the
protective effect of estrogen against OA lesions.
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